Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China

Zhang, H W; Yin, J H; Li, Y T; Li, C Z; Ren, H; Gu, C Y; Wu, H Y; Liang, X S; Zhang, P; Zhao, J F; Tan, X J; Lu, W; Schaefer, S; Cao, G W
December 2008
Gut;Dec2008, Vol. 57 Issue 12, p1713
Academic Journal
Background and aims: The major risk factors for acute hepatitis B (AHB) in China and the viral factors determining the progression from acute to chronic hepatitis B remain largely unknown. Methods: Epidemiological studies within a population- based surveillance for AHB in adults were performed in Shanghai, China, including 294 patients, 588 matched controls and 572 family members of the patients. Results: Invasive medical procedures, household contact with hepatitis B virus (HBV) carriers, body care and beauty treatments, and lack of HBV vaccination were independently associated with AHB. Among those risks, pedicure in bath centres emerged. Sixty-eight of 128 patients with AHB were genotyped including 33 with HBV B2 and 35 with HBV C2. Twenty-five (8.50%) of the 294 patients, including 20 with HBV C2 and 5 with HBV 82 (p = 0.013), progressed to chronic infection. Multivariate analysis showed that HBV C2 was independently associated with chronicification of AHB. Patients with HBV B2 were younger and there was a higher proportion of women than those with HBV C2. The prevalence of HBV 82 was higher in the patients than in neighbourhood chronic carriers. The chronic carriers with HBV B2 showed higher viral loads, higher hepatitis B e antigen )HBeAg) seropositivity, and with higher proportion in men than those with HBV C2, implying that sexual contact plays a role in the transmission of HBV B2. Phylogenetic analysis showed that HBV C2 was frequently involved in transmissions within households. Conclusions: Despite lower viral load and HBeAg status in the chronic carriers, HBV C2 was more prone to causing chronic infection than was HBV 82.


Related Articles

  • HB-Vax II.  // Royal Society of Medicine: Medicines;2002, p278 

    The article presents information on HB-Vax II, a proprietary, prescription-only preparation of hepatitis B vaccine. It can be used to give protection from hepatitis B in people at risk, and is available in a form for injection.

  • Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan. Attaullah, Sobia; Khan, Sanaullah; Naseemullah; Sultan Ayaz; Khan, Shahid Niaz; Ali, Ijaz; Hoti, Naseruddin; Siraj, Sami // Virology Journal;2011, Vol. 8 Issue 1, p275 

    Background: Hepatitis B Virus (HBV) may progress to serious consequences and increase dramatically beyond endemic dimensions that transmits to or from health care workers (HCWs) during routine investigation in their work places. Basic aim of this study was to canvass the safety of HCWs and...

  • Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Whittle, Hilton; Jaffar, Shabbar; Wansbrough, Michael; Mendy, Maimuna; Dumpis,, Uga; Collinson, Andrew; Hall, Andrew // BMJ: British Medical Journal (International Edition);9/14/2002, Vol. 325 Issue 7364, p569 

    Abstract Objective: To determine the duration of protection from hepatitis B vaccine given in infancy and early childhood. Design: Cross sectional serological study of hepatitis B virus infection in children of various ages 14 years after the start of a trial of vaccination regimens. Setting:...

  • The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. Al-Mekhaizeem, Khalid A.; Miriello, Michael; Sherker, Averell H. // CMAJ: Canadian Medical Association Journal;10/16/2001, Vol. 165 Issue 8, p1063 

    Focuses on hepatitis B core antibody (HBcAb), hepatitis B surface antigen (HBsAg), and their relationship to hepatitis B infection. The use of vaccinations; Results of hepatitis B screening in hospital patients.

  • Response to Hepatitis B Vaccine in HIV-1-Positive Subjects Who Test Positive for Isolated Antibody to Hepatitis B Core Antigen: Implications for Hepatitis B Vaccine Strategies. Gandhi, Rajesh T.; Wurcel, Alysse; Hang Lee; Mcgovern, Barbara; Shopis, Janet; Geary, Meghan; Sivamurthy, Rohini; Sax, Paul E.; Ukomadu, Chinweike // Journal of Infectious Diseases;5/1/2005, Vol. 191 Issue 9, p1435 

    Background. Whether human immunodeficiency virus type 1 (HIV-1)-positive subjects who test positive for isolated antibody to hepatitis B core antigen (anti-HBc) should be vaccinated with hepatitis B vaccine is not certain. Development of an anamnestic response after vaccination would suggest...

  • Family Physician Acceptance of Universal Hepatitis B Immunization of Infants. Freed, Gary L.; Bordley, W. Clayton; Clark, Sarah J.; Konrad, Thomas R. // Journal of Family Practice;Feb1993, Vol. 36 Issue 2, p153 

    Background. The incidence of hepatitis B infection has risen 37% over the last decade; 300,000 new infections and 5000 deaths occur annually in the United States. Because immunization programs that targeted high-risk groups failed to abate this increase, the Centers for Disease Control (CDC)...

  • Paths toward hepatitis B immunization in South Korea and Taiwan. Tzung-wen Chen // Clinical & Experimental Vaccine Research;Jul2013, Vol. 2 Issue 2, p76 

    South Korea and Taiwan have had similar experiences of economic development in the post-war era. The two societies have also successfully overcome the threat of liver cancer by using mass hepatitis B vaccinations. However, to reach their current states, they followed different directions, and...

  • Can Specific Heterologous Immunity Boost Hepatitis B Vaccine Responses? Diepolder, Helmut M. // Journal of Infectious Diseases;8/1/2008, Vol. 198 Issue 3, p297 

    The article discusses the effect of a specific heterologous immunity in boosting Hepatitis B Vaccinne responses. The currently licensed hepatitis B vaccines are highly effective and induce protective antibody titers in 95% of vaccines after three immunizations. Moreover, immunogenicity of the...

  • Does Hepatitis B Vaccination Protection Continue after 15 Years? McMahon, B. J.; Bruden, D.L.; Petersen, K.M.; Bulkow, L.R.; Parkinson, A.J.; Nainan, O.; Khristova, M.; Zanis, C.; Peters, H.; Margolis., H.S. // Annals of Internal Medicine;3/1/2005, Vol. 142 Issue 5, pI34 

    This article explores whether hepatitis B vaccination continues after 15 years. Hepatitis B virus causes inflammation of the liver. The virus spreads through contact with infected body fluids, such as through sexual intercourse, open cuts, or scratches, or from mother to baby at birth. Most...


Read the Article


Sign out of this library

Other Topics